NASDAQ:AMRX opened at $3.19 on Friday. The stock has a market capitalization of $966.31 million, a price-to-earnings ratio of 159.50, a PEG ratio of 0.16 and a beta of 1.17. Amneal Pharmaceuticals has a fifty-two week low of $2.90 and a fifty-two week high of $5.99. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.46 and a current ratio of 2.31. The company’s 50 day moving average is $3.62.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported $0.10 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.10. The firm had revenue of $497.63 million during the quarter, compared to analyst estimates of $500.68 million. Amneal Pharmaceuticals had a return on equity of 53.73% and a net margin of 0.08%. As a group, equities research analysts forecast that Amneal Pharmaceuticals will post 0.74 EPS for the current fiscal year.
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
- Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
- Ride Out The Recession With These Dividend Kings
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.